Your email has been successfully added to our mailing list.

×
-0.000418935902806936 -0.00209467951403438 -0.00335148722245489 -0.00293255131964811 -0.00293255131964811 -0.00293255131964811 -0.00293255131964811 -0.00293255131964811
Stock impact report

Amicus: Teva Settlement Clears Revenue Path Forward For Galafold [Seeking Alpha]

Amicus Therapeutics, Inc. (FOLD) 
Last amicus therapeutics, inc. earnings: 11/11 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.amicusrx.com/investor-relations
Company Research Source: Seeking Alpha
Follow Play 13min Summary Amicus Therapeutics settled litigation with Teva, preventing a generic version of Galafold for Fabry Disease until 2037, ensuring revenue growth. Pombiliti + Opfolda approved for late-onset Pompe Disease, with potential label expansion to children and infants with successful studies, boosting market opportunity. Galafold sales grew 17% YoY to $110.8 million in Q2 of 2024, with full-year 2024 revenue growth guidance raised to 14%-18%. The global Pompe Disease treatment market size is projected to grow to $1.53 billion by 2032. Looking for more investing ideas like this one? Get them exclusively at Biotech Analysis Central. Learn More » Jacob Wackerhausen Amicus Therapeutics NASDAQ: FOLD ) now has a lot of breathing room with respect to its approved drug Galafold [migalastat] for the treatment of patients with Fabry disease. That's because it was just announced that it has settled its litigation against This article is published by Terry Show less Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
FOLD alerts

from News Quantified
Opt-in for
FOLD alerts

from News Quantified